Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 13/20 | 0.53 |
| ▸ | GAA | P10253 | 6/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | GLA | P06280 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19132858 | 0.83 | SMN1; SMN2 (0.54) | SMN1; SMN2KEAP1MAPTGAARAB9A | |
| SCHEMBL20856609 | 0.82 | SMN1; SMN2 (0.56) | SMN1; SMN2KEAP1MAPTGAARAB9A | |
| SCHEMBL2705429 | 0.80 | EPHX2 (0.45) | SMN1; SMN2MAPTRAB9A | |
| SCHEMBL799939 | 0.80 | RAB9A (0.58) | SMN1; SMN2MAPTGAARAB9AKDM4E | |
| SCHEMBL9518625 | 0.79 | SMN1; SMN2 (0.53) | SMN1; SMN2KEAP1MAPTGAARAB9A | |
| SCHEMBL10220011 | 0.79 | GFER (0.56) | SMN1; SMN2MAPTGAARAB9AKDM4E | |
| SCHEMBL7873642 | 0.79 | PPARA (0.51) | SMN1; SMN2MAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL8355818 | 0.79 | HTT (0.56) | MAPTGAACA1CA2CA4 | |
| SCHEMBL799878 | 0.79 | NPC1 (0.51) | SMN1; SMN2MAPTGAARAB9AKDM4E | |
| SCHEMBL13824620 | 0.79 | APP (0.48) | SMN1; SMN2MAPTRAB9ANPC1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271969-A1 | NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| WO-2021057816-A1 | NUCLEIC ACID APTAMER MOLECULE | 华东理工大学 | 2021-04-01 | — | — | WO | disclosed |
| US-20070249639-A1 | Use of 9H-Purine-2,6-Diamine Derivatives in the Treatment of Proliferative Diseases and Novel 9H-Purine-2,6-Diamine Derivatives | BAENTELI ROLF | 2007-10-25 | — | — | US | disclosed |
| EP-1734968-A2 | USE OF 9H-PURINE-2,6-DIAMINE DERIVATIVES IN THE TREATMENT OF PROLIFERATIVE DISEASES AND NOVEL 9H-PURINE-2,6-DIAMINE DERIVATIVES | Novartis AG (CH) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005097135-A2 | USE OF 9H-PURINE-2,6-DIAMINE DERIVATIVES IN THE TREATMENT OF PROLIFERATIVE DISEASES AND NOVEL 9H-PURINE-2,6-DIAMINE DERIVATIVES | NOVARTIS AG (CH) | 2005-10-20 | — | — | WO | disclosed |
| EP-0107622-B1 | BENZODIOXOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CIBA-GEIGY AG (CH) | 1987-11-11 | — | — | EP | disclosed |
| US-4600709-A | ANTIEDEMIC, HYPOTENSIVE, DIURETIC | CIBA-GEIGY AG (CH) | 1986-07-15 | — | — | US | disclosed |
| EP-0107622-A1 | Benzodioxole derivatives, process for their preparation and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1984-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271969-A1 | NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | NR5A1, WEE1, SHBG | SMN1; SMN2 4697/4885KEAP1 468/4885MAPT 4121/4885 |
| US-20070249639-A1 | Use of 9H-Purine-2,6-Diamine Derivatives in the Treatment of Proliferative Diseases and Novel 9H-Purine-2,6-Diamine Derivatives | HPRT1, NUDT1, DPYD | SMN1; SMN2 690/4885KEAP1 3907/4885MAPT 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.